Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Exchange Rate Effect: 2010-2025

Historic Exchange Rate Effect for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to -$302,000.

  • Anika Therapeutics' Exchange Rate Effect fell 189.61% to -$302,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $21,000, marking a year-over-year decrease of 86.71%. This contributed to the annual value of -$48,000 for FY2024, which is 160.76% down from last year.
  • As of Q3 2025, Anika Therapeutics' Exchange Rate Effect stood at -$302,000, which was down 187.54% from $345,000 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Exchange Rate Effect high stood at $345,000 for Q2 2025, and its period low was -$302,000 during Q3 2025.
  • Its 3-year average for Exchange Rate Effect is $16,545, with a median of $27,000 in 2023.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first skyrocketed by 850.00% in 2023, then crashed by 929.63% in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Exchange Rate Effect stood at $118,000 in 2021, then tumbled by 158.47% to -$69,000 in 2022, then soared by 210.14% to $76,000 in 2023, then slumped by 271.05% to -$130,000 in 2024, then crashed by 189.61% to -$302,000 in 2025.
  • Its Exchange Rate Effect was -$302,000 in Q3 2025, compared to $345,000 in Q2 2025 and $108,000 in Q1 2025.